Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Praxis Precision Medicines (PRAX) over the last 6 years, with Dec 2024 value amounting to $41.4 million.

  • Praxis Precision Medicines' Share-based Compensation fell 40.10% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year decrease of 15.41%. This contributed to the annual value of $41.4 million for FY2024, which is 66.39% up from last year.
  • According to the latest figures from FY2024, Praxis Precision Medicines' Share-based Compensation is $41.4 million, which was up 66.39% from $24.9 million recorded in FY2023.
  • In the past 5 years, Praxis Precision Medicines' Share-based Compensation ranged from a high of $41.4 million in FY2024 and a low of $5.2 million during FY2020.
  • In the last 3 years, Praxis Precision Medicines' Share-based Compensation had a median value of $28.6 million in 2022 and averaged $31.6 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 680.09% in 2020, then declined by 13.07% in 2023.
  • Yearly analysis of 5 years shows Praxis Precision Medicines' Share-based Compensation stood at $5.2 million in 2020, then surged by 335.48% to $22.7 million in 2021, then increased by 26.00% to $28.6 million in 2022, then declined by 13.07% to $24.9 million in 2023, then spiked by 66.39% to $41.4 million in 2024.